Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Singapore Medical: Offer Doc Out; 90% Conditionality Firmed

Singapore Medical (SMG SP): "Not Fair But Reasonable" Says IFA. TLW Needs To Bump

Singapore Medical Extends Offer As Tendering Surprises

Quiddity Advisors

Event-Driven

<ul>
<li>Healthcare provider <strong><a href="https://www.smartkarma.com/entities/singapore-medical-group-ltd" target="_blank" data-smartkarma-citation="entities:7441:1" rel="noopener">Singapore Medical (SMG SP)</a></strong> has announced a voluntary conditional general offer from TLW Success, an entity equally controlled by three senior members of management.</li>
<li>TLW is offering S$0.37/share, a 13.8% premium to last close. Shareholders are afforded an unlisted scrip option.</li>
<li>TLW shareholders hold 16.49%. Irrevocables another 35.18%, or 51.67% all-in. The Offer is conditional on 90% of shares out held by the Offeror. The acceptance level condition may be reduced. </li>
</ul>


Healthcare provider Singapore Medical (SMG SP) has announced a voluntary conditional general offer from TLW Success, an entity equally controlled by three senior members of management.
TLW is offering S$0.37/share, a 13.8% premium to last close. Shareholders are afforded an unlisted scrip option.
TLW shareholders hold 16.49%. Irrevocables another 35.18%, or 51.67% all-in. The Offer is conditional on 90% of shares out held by the Offeror. The acceptance level condition may be reduced. 


Singapore Medical: Management's Low-Balled Buyout